International Journal of Applied Research
Vol. 2, Issue 7, Part H (2016)
Serum cholinesterase as biomarker in liver disorders
Liver disorders are the major leading cause of morbidity and mortality worldwide. Biochemical tests for the assessment of liver function include measurement of serum total bilirubin (TB), serum aspartate and alanine transaminases (SGOT & SGPT), serum alkaline phosphatase (ALP), serum protein and albumin. However these tests are often abnormal in patients with clinical problems other than liver dysfunction. Serum cholinesterase or Pseudocholinesterase (PChE) is synthesized in liver and secreted into plasma. Hepatocellular impairment will reflect a decreased enzyme activity. The study group consisted of 120 subjects, of age groups 20-60 years and of both sexes. Of these, 40 were viral hepatitis cases (Group 2), 40 were cirrhosis of liver cases (Group 3) and 40 were healthy individuals as controls (Group 1). Serum PChE, TB, SGOT, SGPT, ALP were estimated in all the individuals. Results showed that the serum levels of PChE are decreased in both Group 2 & Group 3 patients (Group 3 > Group 2) when compared to Group 1. Other Lft’s showed increase in both groups when compared to controls. The decrease in PChE is extremely statistically significant in both groups when compared to controls (p < 0.0001). Hence PChE can be used as a routine diagnostic test besides other liver function tests for investigation of liver disorders.
How to cite this article:
Dr. T Anil Kumar,, Dr. B Lakshmi Keerthana. Serum cholinesterase as biomarker in liver disorders. Int J Appl Res 2016;2(7):563-565.